| Previous close | 2.9000 |
| Open | 2.9200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.8300 - 3.0199 |
| 52-week range | 1.8000 - 3.5000 |
| Volume | |
| Avg. volume | 64,970 |
| Market cap | 93.621M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.78 |
PR NewswireResearch Solutions to Announce Third Quarter Fiscal 2024 Results on Thursday, May 9, 2024
Research Solutions, Inc. (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, will hold a conference call to discuss its financial results for the fiscal 2024 third quarter ended March 31, 2024, on Thursday, May 9, 2024, at 5:00 p.m. ET. A press release containing the company's financial results will be issued following the market close and prior to the call.
PR NewswireResearch Solutions Unveils AI Platform for Automated Clinical Trial Landscape Reports
Research Solutions (NASDAQ: RSSS), a trusted partner providing cloud-based workflow solutions to accelerate research for R&D-driven organizations, today launches their new Clinical Trial Landscape software solution, making clinical trial information more accessible, insightful, and actionable. Clinical trials are essential research studies that assess the efficacy and safety of medical interventions, informing regulatory decisions, guiding healthcare practices, and advancing medical knowledge an
Simply Wall St.With 37% stake, Research Solutions, Inc. (NASDAQ:RSSS) seems to have captured institutional investors' interest
Key Insights Significantly high institutional ownership implies Research Solutions' stock price is sensitive to their...
